Literature DB >> 33965354

Focal splenic lesions: Imaging spectrum of diseases on CT, MRI and PET/CT.

Maxime Barat1, Christine Hoeffel2, Mathilde Aissaoui3, Anthony Dohan4, Amar Oudjit3, Raphael Dautry3, Anita Paisant5, Brice Malgras6, Anne-Ségolène Cottereau7, Philippe Soyer4.   

Abstract

The spleen can be affected by a variety of diseases. Some of them are readily identified as variations of normal or benign diseases on imaging. However, for a substantial number of focal splenic abnormalities, the diagnosis can be difficult so that histopathologic analysis may be required for a definite diagnosis. In this review, the typical splenic abnormalities that can be diagnosed with imaging with a high degree of confidence are illustrated. The complementary role of computed tomography (CT), magnetic resonance imaging and positron emission tomography/CT that helps make a diagnostic approach is discussed. Finally, current applications and future trends of radiomics and artificial intelligence for the diagnosis of splenic diseases are addressed.
Copyright © 2021 Société française de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Biopsy; Magnetic resonance imaging; Positron-emission tomography; Splenic diseases; Tomography, X-ray computed

Year:  2021        PMID: 33965354     DOI: 10.1016/j.diii.2021.03.006

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  2 in total

1.  A Machine Learning-Based Approach for Classification of Focal Splenic Lesions Based on Their CT Features.

Authors:  Silvia Burti; Alessandro Zotti; Federico Bonsembiante; Barbara Contiero; Tommaso Banzato
Journal:  Front Vet Sci       Date:  2022-05-02

2.  Radiomics Features of the Spleen as Surrogates for CT-Based Lymphoma Diagnosis and Subtype Differentiation.

Authors:  Johanna S Enke; Jan H Moltz; Melvin D'Anastasi; Wolfgang G Kunz; Christian Schmidt; Stefan Maurus; Alexander Mühlberg; Alexander Katzmann; Michael Sühling; Horst Hahn; Dominik Nörenberg; Thomas Huber
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.